Erratum: Intravenous Iron in Patients Undergoing Maintenance Hemo-dialysis (New England Journal of Medicine (2019) 380 (447-458) DOI: 10.1056/NEJMoa1810742);Intravenous iron in patients undergoing maintenance hemodialysis

New England Journal of Medicine

Volumn 380, Issue 5, 2019, Pages 447-458

  Macdougall, Iain C ^a   White, Claire ^a   Anker, Stefan D ^h   Bhandari, Sunil ^b   Farrington, Kenneth ^c,d   Kalra, Philip A ^e   McMurray, John J V ^f   Murray, Heather ⁱ   Tomson, Charles R V ^g   Wheeler, David C ^a   Winearls, Christopher G ^g   Ford, Ian ⁱ  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b HULL AND EAST YORKSHIRE HOSPITALS NHS TRUST   (United Kingdom)

^c LISTER HOSPITAL   (United Kingdom)

^d UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

^e SALFORD ROYAL NHS FOUNDATION TRUST   (United Kingdom)

^f UNIVERSITY OF GLASGOW   (United Kingdom)

^g FREEMAN HOSPITAL   (United Kingdom)

^h CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

ⁱ UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; FERRITIN; IRON SACCHARATE; TRANSFERRIN;

ADULT; ARTICLE; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DRUG MEGADOSE; DRUG SAFETY; END STAGE RENAL DISEASE; FEMALE; FERRITIN BLOOD LEVEL; FOLLOW UP; HAZARD RATIO; HEART FAILURE; HEART INFARCTION; HEMODIALYSIS; HOSPITALIZATION; HUMAN; INFECTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; THROMBOSIS; TRANSFERRIN BLOOD LEVEL; VASCULAR ACCESS THROMBOSIS; AGED; ANEMIA; BLOOD; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DOSE RESPONSE; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; SINGLE BLIND PROCEDURE;

ADMINISTRATION, INTRAVENOUS; ADULT; AGED; ANEMIA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; FERRIC OXIDE, SACCHARATED; FERRITINS; FOLLOW-UP STUDIES; HEMATINICS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS; SINGLE-BLIND METHOD; TRANSFERRIN;

EID: 85056137737     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMx180044     Document Type: Erratum

References (33)

1. Wish JB, Aronoff GR, Bacon BR, et al. Positive iron balance in chronic kidney disease: how much is too much and how to tell? Am J Nephrol 2018;47:72-83.
2. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl 2012;2:279-335.
3. Bailie GR, Larkina M, Goodkin DA, et al. Variation in intravenous iron use internationally and over time: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2013; 28:2570-9.
4. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339:584-90.
5. Coyne DW. The health-related quality of life was not improved by targeting higher hemoglobin in the Normal Hema-tocrit Trial. Kidney Int 2012;82:235-41.
6. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355:2085-98.
7. Pfeffer MA, Burdmann EA, Chen C-Y, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009;361:2019-32.
8. Drüeke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006;355:2071-84.
9. Macdougall IC, Bircher AJ, Eckardt KU, et al. Iron management in chronic kidney disease: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference. Kidney Int 2016;89:28-39.
10. Ganguli A, Kohli HS, Khullar M, Lal Gupta K, Jha V, Sakhuja V. Lipid peroxidation products formation with various intravenous iron preparations in chronic kidney disease. Ren Fail 2009;31:106-10.
11. Del Vecchio L, Longhi S, Locatelli F. Safety concerns about intravenous iron therapy in patients with chronic kidney disease. Clin Kidney J 2016;9:260-7.
12. Drakesmith H, Prentice AM. Hepcidin and the iron-infection axis. Science 2012; 338:768-72.
13. Neven E, De Schutter TM, Behets GJ, Gupta A, D'Haese PC. Iron and vascular calcification: is there a link? Nephrol Dial Transplant 2011;26:1137-45.
14. Hansson L, Hedner T, Dahlöf B. Prospective Randomized Open Blinded Endpoint (PROBE) study: a novel design for intervention trials. Blood Press 1992;1: 113-9.
15. Macdougall IC, White C, Anker SD, et al. Randomized trial comparing proactive, high-dose versus reactive, low-dose intravenous iron supplementation in hemodialysis (PIVOTAL): study design and baseline data. Am J Nephrol 2018;48:260-8.
16. National Institute for Health and Care Excellence (NICE). Chronic kidney disease: managing anaemia. June 3, 2015 (https://www.nice.org.uk/guidance/ng8/resources/chronic-kidney-disease-managing -anaemia-pdf-51046844101).
17. Lin DY, Wei LJ, Yang I, Ying Z. Semi-parametric regression for the mean and rate functions of recurrent events. J R Stat Soc B 2000;62:711-30.
18. Ghosh D, Lin DY. Nonparametric analysis of recurrent events and death. Biometrics 2000;56:554-62.
19. Miskulin DC, Tangri N, Bandeen-Roche K, et al. Intravenous iron exposure and mortality in patients on hemodialysis. Clin J Am Soc Nephrol 2014;9:1930-9.
20. Bailie GR, Larkina M, Goodkin DA, et al. Data from the Dialysis Outcomes and Practice Patterns Study validate an association between high intravenous iron doses and mortality. Kidney Int 2015;87: 162-8.
21. Kalantar-Zadeh K, Regidor DL, McAl-lister CJ, Michael B, Warnock DG. Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol 2005;16:3070-80.
22. Hougen I, Collister D, Bourrier M, et al. Safety of intravenous iron in dialysis: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2018;13:457-67.
23. Brookhart MA, Freburger JK, Ellis AR, Wang L, Winkelmayer WC, Kshirsagar AV. Infection risk with bolus versus maintenance iron supplementation in hemodialysis patients. J Am Soc Nephrol 2013;24: 1151-8.
24. Kshirsagar AV, Freburger JK, Ellis AR, Wang L, Winkelmayer WC, Brookhart MA. Intravenous iron supplementation practices and short-term risk of cardiovascular events in hemodialysis patients. PLoS One 2013;8(11):e78930.
25. Dalal J, Katekhaye V, Jain R. Effect of ferric carboxymaltose on hospitalization and mortality outcomes in chronic heart failure: a meta-analysis. Indian Heart J 2017;69:736-41.
26. Anker SD, Kirwan BA, van Veldhuisen DJ, et al. Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis. Eur J Heart Fail 2018;20:125-33.
27. Qian C, Wei B, Ding J, Wu H, Wang Y. The efficacy and safety of iron supplementation in patients with heart failure and iron deficiency: a systematic review and meta-analysis. Can J Cardiol 2016;32: 151-9.
28. Cunha GJL, Rocha BML, Menezes Falcão L. Iron deficiency in chronic and acute heart failure: a contemporary review on intertwined conditions. Eur J Intern Med 2018;52:1-7.
29. Cassat JE, Skaar EP. Iron in infection and immunity. Cell Host Microbe 2013; 13:509-19.
30. Stefanova D, Raychev A, Deville J, et al. Hepcidin protects against lethal Escherichia coli sepsis in mice inoculated with isolates from septic patients. Infect Immun 2018; 86(7):e00253-18.
31. Nairz M, Schroll A, Haschka D, et al. Genetic and dietary iron overload differentially affect the course of Salmonella typhimurium infection. Front Cell Infect Micro-biol 2017;7:110.
32. Cross JH, Bradbury RS, Fulford AJ, et al. Oral iron acutely elevates bacterial growth in human serum. Sci Rep 2015;5:16670.
33. US-DOPPS (Dialysis Outcomes and Practice Patterns Study) practice monitor: monthly IV iron dose received (90 day average), continuous (mg). April 2018 (https://www.dopps.org/DPM/Files/sum_IVIRON90DAY_overallTAB.htm).